## CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-005

MICROBIOLOGY REVIEW(S)

## REVIEW FOR DIVISION OF DERMATOLOGIC AND DENTAL DRUG PRODUCTS, HFD-540 OFFICE OF NEW DRUG CHEMISTRY, MICROBIOLOGY STAFF, HFD-805 MICROBIOLOGISTS'S REVIEW NO. 1

## September 15, 1999

MICR	OBIOL	OGY REVIEWER: Carol K. Vince	ant .		
A.	1.	NDA No.: 21-005	•	<b>%</b>	
	•	DRUG PRODUCT NAME:	Solarase [dicl	ofenac sodium] gel	
	APPLICANT:		MANUFACTURER:		
	2425 5	harmaceutical Corporation Skymark Avenue ssauga, Ontario, Canada '6		· · · · · · · · · · · · · · · · · · ·	
	2.	DOSAGE FORM AND ROUTE OF ADMINISTRATION: Non-sterile, topical gel.			
	3.	METHOD(s) OF STERILIZAT Not applicable; non-sterile, topics		benzyl alcohol.	
	4. PHARMACOLOGICAL CATEGORY AND/OR PRINCIPAL INDICATION: Treatment of actinic keratotic lesions.				
	5.	DRUG PRIORITY CLASSIFIC	CATION: 3 S		
B.	1. 2. 3. 4. 5.	DOCUMENT DATE: DOCUMENT RECEIVED FOR AMENDMENT: AMENDMENT RECEIVED FOR RELATED DOCUMENTS: DMF 10836, July 19, 19 DMF 11366, July 19, 19	OR REVIEW:	Oct 20, 1998 July 9, 1999 September 3, 1999 September 7, 1999	
C.	REM	REMARKS: The original microbiology consult for NDA 21-005 expressed concerns that the excipient, sodium hyaluronate, was In the current formulation and description for this excipient, the manufacturing method is entirely by There are therefore, no " ' to have microbiological concerns about.			
specifi comm	s topical, ications fo itment to		te microbial limits. ` no microbiological c	while we are recommending a change to the release concerns with the manufacture of this product. A asis is acceptable.	
Orig. NDA 21-005 HFD-160/Consult/CKVincent [HFD-805] HFD-540/MGautam-Basak/DeCamp/KDWhite Drafted by: CKVincent/09-10-99/  Filename:NDA21-005  Carol K. Vincent Review Microbiologist [HFD-805] Filename:NDA21-005					

## WITHHOLD PAGE (S)